INT186135

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.34
First Reported 2005
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 5
Disease Relevance 3.27
Pain Relevance 0.74

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (ITGAL) cell adhesion (ITGAL) plasma membrane (ITGAL)
Anatomy Link Frequency
T cells 6
plaques 2
ITGAL (Homo sapiens)
Pain Link Frequency Relevance Heat
Inflammation 40 96.92 Very High Very High Very High
psoriasis 166 88.40 High High
Inflammatory response 1 74.12 Quite High
backache 1 73.40 Quite High
headache 4 63.92 Quite High
Arthritis 117 63.08 Quite High
methotrexate 12 62.64 Quite High
cytokine 48 56.56 Quite High
corticosteroid 2 42.92 Quite Low
abatacept 3 5.76 Low Low
Disease Link Frequency Relevance Heat
Adhesions 17 99.52 Very High Very High Very High
Psoriasis 197 97.24 Very High Very High Very High
INFLAMMATION 39 96.92 Very High Very High Very High
Disease 53 81.96 Quite High
Infection 38 76.68 Quite High
Vomiting 6 74.40 Quite High
Nasopharyngitis 1 74.08 Quite High
Low Back Pain 2 73.40 Quite High
Autoimmune Disease 5 70.24 Quite High
Headache 4 63.92 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Efalizumab inhibits T-cell activation, cutaneous trafficking, and adhesion to keratinocytes through the blockade of LFA-1/ICAM-1 binding, steps in the immunologic cascade that lead to the formation of the psoriatic plaques (Menter et al 2005).
Negative_regulation (blockade) of LFA-1 Binding (binding) of in plaques associated with psoriasis and adhesions
1) Confidence 0.34 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727906 Disease Relevance 0.74 Pain Relevance 0.07
This drug binds to CD11a on T cells blocking the interaction between LFA-1 and intercellular adhesion molecule 1 (ICAM-1), its partner molecule for adhesion.
Negative_regulation (blocking) of LFA-1 Binding (interaction) of in T cells associated with adhesions
2) Confidence 0.23 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721342 Disease Relevance 0.31 Pain Relevance 0.03
The third mechanism is unrelated to inhibition of HMG-CoA reductase, and consist in blocking the interaction between LFA-1 and ICAM-1 adhesion molecules [30], which is crucial to stabilize antigen presenting cell/T-cell contact during antigen presentation and to regulate the traffic of leukocytes during homeostatic and inflammatory conditions [31,32].
Negative_regulation (blocking) of LFA-1 Binding (interaction) of in T-cell associated with inflammation and adhesions
3) Confidence 0.09 Published 2009 Journal Trials Section Body Doc Link PMC2705367 Disease Relevance 0.44 Pain Relevance 0.11
Efalizumab is a humanized monoclonal IgG antibody that binds to the alpha-subunit (CD11) of LFA-1 and prevents LFA-1 binding to ICAM-1.
Negative_regulation (prevents) of LFA-1 Binding (binding) of
4) Confidence 0.08 Published 2005 Journal J Immune Based Ther Vaccines Section Body Doc Link PMC1208938 Disease Relevance 1.25 Pain Relevance 0.38
Thus, blocking LFA-1 interactions has the dual effect of blocking activation as well as migratory activity of inflammatory T cells.
Negative_regulation (blocking) of LFA-1 Binding (interactions) of in T cells associated with inflammation
5) Confidence 0.03 Published 2008 Journal Indian Journal of Pharmacology Section Body Doc Link PMC2792605 Disease Relevance 0.46 Pain Relevance 0.14

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox